Gastrointestinal Cancer

Olverembatinib showed antitumor activity in patients with TKI-resistant, SDH-deficient GISTs and paraganglioma.

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Olivia Aranha, MD, PhD, discusses data supporting the use of HIPEC for patients with peritoneal carcinomatosis in gastrointestinal malignancies.

Michael Iglesia, MD, PhD, discusses the potential role of disease etiology in frontline HCC treatment decision-making.

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Avzivi, a monoclonal antibody referencing bevacizumab.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Arndt Vogel, MD, on the final overall survival data for camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.

Rivoceranib plus camrelizumab maintained a survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

Zanidatamab continued to show confirmed responses, disease control, and prolonged overall survival in pretreated HER2+ biliary tract cancer.

Perioperative chemotherapy with FLOT improved OS vs neoadjuvant chemoradiation with CROSS in resectable esophageal cancer.

The FDA accepted the resubmission of the BLA for first-line zolbetuximab in CLDN18.2-positive, HER2-negative, advanced gastric or GEJ adenocarcinoma.

Pitavastatin, an FDA-approved statin, may inhibit pathways that contribute to IL-33 production, which has been shown to contribute to cancer development.

Daniel M. Halperin, MD, discusses the FDA approval of lutetium Lu 177 dotatate for pediatric patients with SSTR-positive GEP-NETs.

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

Haeseong Park, MD, MPH, discusses the rationale for combining epacadostat with preoperative chemoradiation in locally advanced rectal cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss how to factor in trastuzumab deruxtecan in advanced biliary tract cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss considering factors for immunotherapy agents in advanced biliary tract cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the clinical implications of 3-year survival data from TOPAZ-1 in advanced biliary tract cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient put the TOPAZ-1 data into context for patients with advanced biliary tract cancer.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, discuss a case of advanced biliary tract cancer with a patient.

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, and a patient discuss prognosis and standard-of-care treatment for patients with advanced biliary tract cancer.

Zanidatamab has received priority review from the FDA for the treatment of patients with HER2-positive metastatic biliary tract cancer.

CT041 was safe and showcased early signals of antitumor activity in heavily pretreated patients with metastatic pancreatic cancer.

Kohei Shitara, MD, discusses the background of the phase 3 CheckMate 649 study in advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma.

Haeseong Park, MD, MPH, discusses findings from a phase 1 study of epacadostat with preoperative chemoradiation in locally advanced rectal cancer.

Kara N. Maxwell, MD, PhD, discusses the accessibility of genetic testing in the community setting for patients with metastatic prostate cancer.

Kian-Huat Lim, MD, PhD, discusses the current standard of care for patients with resectable or borderline resectable pancreatic cancer.

The FDA has withdrawn the approval of infigratinib for previously treated, FGFR2-positive, advanced cholangiocarcinoma.